Syncona collaborates with UCL Business to form Autolus.
M2 EQUITYBITES-January 26, 2015-Syncona collaborates with UCL Business to form Autolus
(C)2015 M2 COMMUNICATIONS http://www.m2.com
United Kingdom-based Syncona has collaborated with UCL Business, the wholly-owned technology transfer company of University College London, to establish Autolus Limited, a biopharmaceutical company, it was reported on Friday.
The company will work towards the development and commercialisation of next-generation engineered T-cell therapies for haematological and solid tumours. The company has been formed based on the work of Dr Martin Pule, an academic clinical haematologist and thought-leader in T-cell engineering. Syncona has committed GBP30m to Autolus in a Series A financing.
Martin Pule, chief scientific officer of Autolus and senior lecturer at the UCL Cancer Institute and NIHR University College London Hospitals Biomedical Research Centre, said, 'It is exciting to be involved in Autolus, where we have an opportunity to bring innovative new therapeutic approaches to patients who often have no alternative treatment path. The key will be to remain at the cutting-edge of T-cell engineering to create a new generation of programmed T-cells acting as autonomous agents to kill tumour cells. What we've seen so far in the CAR T-cell field is only the beginning.'
(EUR1 = GBP0.74)
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Jan 26, 2015|
|Previous Article:||Selected Virgin Money mortgage product rates cut and fees waived.|
|Next Article:||Advaxis receives US FDA approval to conduct Phase I clinical trial of ADXS-HER2.|